ARES · Ares Management Corporation

Current Thesis

Ares Management’s fee-growth story supports a recovery thesis, but the market must reclaim the September 4 close before breaching the published $130 weekly-close threshold. The measurable recovery case is a weekly close above $140.15, the 2026-09-04 reference close, before a weekly close below $130. The 2026-09-11 adjusted close of $131.64 leaves that recovery unconfirmed.

The operating evidence remains the 2026-07-31 earnings release: second-quarter fee-related earnings (FRE) of $491.1 million, growing 20% year over year, and assets under management (AUM) of $671 billion at 2026-06-30. Those figures support the earnings-growth component; they do not establish that the equity will recover. The latest close is below the previously published 2026-08-07 close of $136.85 as well as the September 4 reference.

As an inference about attention, the narrative is saturated — the 2026-07-28 acquisition coverage, clustered analyst revisions on 2026-08-03 and Oppenheimer’s 2026-08-27 target increase show an established story. The September 11 close does not confirm renewed demand. This classification concerns coverage, not measured ownership or fund flows. Axios, July 28, Benzinga analyst-action record.

Bullish and bearish views on Ares Management Corporation

The model's bull view on Ares Management Corporation (ARES), in brief: Fee earnings still expanded. Ares’s 2026-07-31 release reported second-quarter FRE growth of 20% year over year, while AUM and fee-paying AUM each grew 17%. These are the reported operating supports for the recovery thesis; another sequential increase in underperforming… The bear view: Price confirmation has deteriorated. The supplied adjusted market series records $131.64 on 2026-09-11 against $140.15 on 2026-09-04. The September 11 snapshot also reports a three-month price decline of 1.4%; operating growth has not produced a positive return over that… Both cases follow in full.

Bull Case

• Fee earnings still expanded. Ares’s 2026-07-31 release reported second-quarter FRE growth of 20% year over year, while AUM and fee-paying AUM each grew 17%. These are the reported operating supports for the recovery thesis; another sequential increase in underperforming investments at the next results would challenge its credit-quality premise.
• Capital formation remained substantial. The same release reported gross second-quarter inflows above $36 billion and available capital of $170 billion at 2026-06-30. the announcement alone does not quantify incremental fee earnings. Ares announcement index.
• Analyst expectations remained constructive. Oppenheimer raised its price target to $162 on 2026-08-27, retaining its Outperform rating. That is Oppenheimer’s forecast, not evidence that the market has accepted the recovery case: the supplied September 11 close remains below the September 4 reference. Benzinga analyst-action record.

Bear Case

• Price confirmation has deteriorated. The supplied adjusted market series records $131.64 on 2026-09-11 against $140.15 on 2026-09-04. The September 11 snapshot also reports a three-month price decline of 1.4%; operating growth has not produced a positive return over that interval.
• Borrower weakness challenges fee growth. Benzinga reported an uptick in underperforming investments on 2026-07-29 alongside concerns about artificial intelligence disrupting borrowers. A further sequential increase at the next quarterly results would confirm deterioration beyond that reported quarter.
• Transaction headlines lack resolving terms. The Financial Times reported Leonard Green & Partners acquisition talks on 2026-07-27; Axios repeated the report on 2026-07-28. The supplied September 5 record contained neither an agreed acquisition nor a clearing price for the $3.4 billion European credit-secondaries process reported on July 27. Neither outcome is established by the available evidence, so neither supplies confirmed earnings accretion or valuation support. Axios acquisition coverage.

Setup & Price Structure

The supplied 2026-09-11 snapshot places the adjusted close at $131.64, 26.1% below the trailing high of $178.13. Its 14-period Relative Strength Index (RSI) is 31.8. That indicator reading describes momentum; it does not establish a reversal.

The $130 threshold is the research invalidation level published on 2026-09-05, not a newly verified chart support. The September 11 close remains above it, but below the dated $136.85 and $140.15 reference closes. A weekly close above $140.15 before a weekly close below $130 would satisfy the defined recovery case.

Coverage clustering is observable in the 2026-08-03 analyst actions and the August 27 Oppenheimer revision. Current short interest, retail participation, moving-average distance and insider transactions are not established in the supplied evidence. The available observations are too limited to support a claim about crowded ownership. Benzinga analyst-action record.

Catalyst Calendar (next 30 days)

• 2026-09-16 — Common dividend record date. The distribution calendar supplied with the July 31 results specifies $1.35 per Class A and non-voting common share, payable 2026-09-30. This is a distribution event, not evidence that borrower quality has improved.
• 2026-09-30 — Common dividend payment. The July 31 distribution declaration schedules payment of the previously declared common dividend. Payment alone does not settle the recovery thesis.
• ~2026-10-28, est. Third-quarter results. This later event is the estimated fundamental checkpoint in the existing coverage; company confirmation of the date is unavailable. The relevant comparison is whether underperforming investments increase sequentially again after the uptick reported on 2026-07-29.

Elapsed catalysts

• 2026-09-16 — Management conference appearance. Ares announced on 2026-09-02 that Chief Executive Officer Michael Arougheti is scheduled to present at the Barclays Global Financial Services Conference at 9:00 a.m. Eastern Time. The event provides a dated opportunity for commentary; the announcement promises no transaction decision or updated credit metrics. Ares September 2 announcement. (passed 4d ago)

What Would Change Our Mind

Failure of the remaining recovery structure ends the price thesis: a weekly close below $130 breaches the threshold published on 2026-09-05. A second sequential increase in underperforming investments at the next quarterly results separately breaks the premise that fee growth can coexist with stabilising credit quality.

The opposite price outcome is also explicit: a weekly close above the 2026-09-04 reference of $140.15 before invalidation completes the defined recovery case. Until either condition occurs, the September 11 close supports a low-probability recovery assessment rather than a confirmed reversal.

Correlation Notes

This is a single-name recovery thesis. Ares identified artificial intelligence, private credit and secondaries as growth themes in its 2026-07-31 commentary, but the supplied record contains no paired return series establishing correlation with an infrastructure or alternative-manager group. The observations are insufficient to attribute the September 11 weakness to a group move.

Borrower quality and fundraising are the documented company channels: the 2026-07-29 report identified underperforming investments, while the July 31 results reported second-quarter inflows above $36 billion. A group-based explanation would require comparative market data; those company disclosures alone do not establish it.